In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the results of the ORBITA-2 Trial and its use in stress echocardiography before PCI. He then discusses the proportion of patients achieving blood pressure (BP) control plateaus despite increasing medication prescriptions. Finally, Dr. Eagle explores the use of rapid initiation and titration in guideline-recommended medical therapy (GRMT) in patients with heart failure with reduced ejection fraction (HFrEF). 

 Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation (AFib). 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the echocardiographic outcomes at five years. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores OCEANIC-AF, a study that analyzes the differences in outcomes in patients with and without prior use of oral anti-coagulants (OACs). 

 Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including:  

• Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up  

• SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI) 

• DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI) 

• STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes 

• RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus  

• API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE) 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle examines the dose-response relationship between smoking and subclinical cardiovascular disease markers. He then discusses how the effect of poor sleep increases diabetes risk in women who have had gestational diabetes. Finally, Dr. Eagle offers a look into imaging post-transcatheter aortic valve replacement (TAVR) in patients who may have valve failure. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients. 

 Subscribe to Eagle’s Eye View